US Patent 11,185,519 (Elafibranor in PBC After Inadequate Response to Ursodeoxycholic Acid): Scope, Claims, and Landscape
What does US 11,185,519 claim in plain scope terms?
US 11,185,519 claims a treatment method for primary biliary cholangitis (PBC) for patients who have an inadequate response to ursodeoxycholic acid (UDCA), using elafibranor as the active agent. The independent claim anchors infringement around three elements:
- Condition: primary biliary cholangitis
- Population modifier: inadequate response to UDCA
- Therapy: administer a therapeutically effective amount of a composition comprising elafibranor
From there, the dependent claims narrow administration form and dose, with explicit dosing carve-ins for 80 mg and 120 mg (including “once daily” language).
What is the patent’s claim architecture and how narrow is it?
Independent claim 1 (core scope)
Claim 1 recites:
- A method for treating PBC
- administering to a subject with PBC and inadequate response to UDCA
- a therapeutically effective amount of a composition comprising elafibranor
Scope implications
- The claim is a use claim (method-of-treatment) with a specific clinical predicate (UDCA inadequate responders).
- It is not limited to a particular formulation beyond “composition comprising elafibranor.”
- It does not require a specific mechanism other than that the administered composition includes elafibranor.
Design-around pressure point
The “inadequate response to UDCA” qualifier is the strongest limiting feature. Any non-UDCA-inadequate population positioning or labeling strategy can be relevant for enforcement, depending on how the claim is construed and how courts treat method-use qualifiers.
Dependent claims 2 (form factor)
Claim 2 limits the “composition” to one of multiple delivery formats, including:
- injectable suspension, gel, oil
- pill, suppository, powder, gel cap, capsule
- aerosol
- “galenic form or device assuring a prolonged and/or slow release”
Scope implications
- Broad delivery coverage; it does not materially restrict formulation design space because it lists many conventional oral and parenteral forms.
- “Prolonged/slow release” language expands coverage to modified-release versions.
Dependent claims 3-10 (dosing and schedule)
These claims narrow elafibranor administration:
- Claim 3: oral once daily, 80 or 120 mg/day
- Claim 4: dose range 70 mg to 130 mg per administration
- Claim 5: 80 mg per administration
- Claim 6: oral (in combination with claim 5)
- Claim 7: 120 mg per administration
- Claim 8: oral (in combination with claim 7)
- Claim 9: oral once daily 80 mg
- Claim 10: oral once daily 120 mg
Scope implications
- The dosing claims cover both fixed doses (80, 120 mg) and a broader per-administration range (70-130 mg).
- Once-daily oral administration is repeatedly specified for 80 and 120 mg, increasing enforceability against standard regimen protocols.
- Even if a product uses non-once-daily schedules or non-oral delivery, claim coverage may still remain under claim 4 (range) and claim 1 (composition generally), subject to claim construction.
What exact infringement-relevant combinations do the claims map to?
| Claim |
Patient predicate |
Administration route |
Schedule |
Dose constraint |
Form constraint |
| 1 |
PBC with inadequate response to UDCA |
Any (implied by “composition”) |
Not required |
“therapeutically effective amount” |
Composition comprising elafibranor (broad) |
| 2 |
Same as claim 1 |
Any listed forms |
Not required |
Not specified |
Explicit list includes oral, injectable, aerosol, sustained/prolonged release devices |
| 3 |
Same as claim 1 |
Oral |
Once daily |
80 or 120 mg/day |
Not limited beyond elafibranor composition |
| 4 |
Same as claim 1 |
Not limited (depends on claim 1) |
Not required |
70-130 mg per administration |
Not limited |
| 5 |
Same as claim 1 |
Not limited (depends on claim 1) |
Not required |
80 mg per administration |
Not limited |
| 6 |
Same as claim 5 |
Oral |
Not required |
80 mg |
Not limited |
| 7 |
Same as claim 1 |
Not limited (depends on claim 1) |
Not required |
120 mg per administration |
Not limited |
| 8 |
Same as claim 7 |
Oral |
Not required |
120 mg |
Not limited |
| 9 |
Same as claim 1 |
Oral |
Once daily |
80 mg |
Not limited |
| 10 |
Same as claim 1 |
Oral |
Once daily |
120 mg |
Not limited |
Enforcement posture
- The patent has stacked coverage: broad claim 1 + formulation claim 2 + regimen-specific claims 3, 9, and 10.
- Practical infringement risk concentrates on treatment protocols for UDCA inadequate responders where elafibranor is used at 80 or 120 mg, especially once daily oral regimens.
How does this patent likely read against typical elafibranor programs and PBC clinical practice?
Without adding external facts, the claim language itself indicates the intended clinical positioning:
- It targets PBC patients who already failed UDCA, aligning with a common regulatory and clinical segmentation for PBC populations.
- It supports conventional dosing at 80 mg and 120 mg with once-daily oral dosing described.
- It anticipates multiple dosage forms including sustained release, which suggests the claims were drafted to cover formulation variants.
What is the likely patent landscape structure around this use?
Even with only the provided claim text, the landscape can be inferred at a structural level:
1) Primary “composition of matter” vs “method-of-use” layers
- Method-of-use patents like US 11,185,519 usually coexist with:
- upstream patents protecting the compound class, synthesis, or crystalline/pharmaceutical compositions, and
- downstream patents protecting specific indications, dosing regimens, patient subgroups, and formulations.
What this means for landscape mapping
- US 11,185,519 functions as an indication and regimen lock for PBC in UDCA inadequate responders.
- It is therefore likely part of a portfolio that also covers elafibranor composition and other uses, but this specific patent is the enforceable hook for the PBC-after-UDCA inadequate responder space.
2) How “UDCA inadequate response” affects landscape threat
This clause narrows the method to a specific medically defined subgroup. Landscape risk assessment for competitors turns on whether their development plan aims at:
- different entry criteria (for example, first-line UDCA add-on or early-stage PBC without requiring inadequate UDCA response), or
- a different active ingredient, or
- a different dosing regimen that attempts to avoid the 80/120 mg once-daily oral pattern.
3) The patent’s “dose perimeter” creates a second barrier
Claim 4 covers a 70-130 mg per administration range. Even if a competitor avoids exact 80 and 120 mg doses, a regimen that lands in the range could still collide with claim 4, depending on route and schedule as construed.
What are the key enforceability and claim-construction pressure points?
Patient qualifier: “inadequate response to UDCA”
This is the primary limiting feature of claim 1. For enforcement, the question becomes whether the accused method is practiced on a subject who meets that predicate at the time of dosing.
Practical portfolio impact
- Any label or protocol that treats non-UDCA-inadequate patients may have a lower direct overlap.
- Any off-label promotion or clinical practice that includes UDCA inadequate responders can create exposure under claim 1 and its dependents.
Administration regimen: oral once daily at 80 or 120 mg
Claims 3, 9, and 10 are tightly aligned to specific regimen language:
- oral once daily
- 80 mg or 120 mg
Practical portfolio impact
- If elafibranor is marketed or used clinically for PBC at those doses, these dependents reinforce enforceability.
Formulation breadth: listed dosage forms plus slow/prolonged release
Claim 2 is broad and reduces the ability to design around with formulation changes.
Practical portfolio impact
- Switching from capsule to sustained-release tablet is likely still within claim 2.
What does the claim set indicate about design-around strategies?
Within the strict bounds of the claim text, the main design-around levers are:
- Avoid the patient predicate: treat PBC without relying on UDCA inadequate response as the dosing justification.
- Avoid the dose perimeter and regimen: use elafibranor outside 70-130 mg per administration and outside once-daily oral 80/120 mg patterns.
- Avoid composition containing elafibranor: use a different active.
- Avoid claimed formulation categories: this is less effective because claim 2 lists many forms and includes prolonged/slow-release devices.
What is the market and investment relevance of this patent’s scope?
US 11,185,519 is a high-value lock because it ties to:
- an active ingredient (elafibranor),
- an advanced patient subgroup (UDCA inadequate responders),
- a chronic indication (PBC),
- and a commercially plausible dosing pattern (oral once daily, 80 or 120 mg).
The patent’s value for portfolio and licensing is strongest for any competitor targeting the same indication segment with elafibranor at conventional doses and routes.
Key Takeaways
- US 11,185,519 protects a method for PBC patients who have an inadequate response to UDCA using elafibranor.
- Claim 1 is broad on dosage amount and formulation beyond requiring “composition comprising elafibranor,” while Claim 2 is broad on dosage forms, listing many conventional formats and slow/prolonged release devices.
- Regimen specificity is concentrated in dependent claims: oral once daily 80/120 mg (claims 3, 9, 10) and a dose range of 70-130 mg per administration (claim 4).
- The strongest scope-limiting qualifier is “inadequate response to ursodeoxycholic acid”, making patient-selection and protocol language central to enforcement risk.
- The patent is designed to withstand formulation workarounds and capture standard clinical dosing practices for elafibranor in UDCA inadequate PBC.
FAQs
1) Does US 11,185,519 cover PBC in general or only UDCA inadequate responders?
It covers PBC with an inadequate response to ursodeoxycholic acid as required by claim 1.
2) Is the dosing limited to 80 and 120 mg only?
No. Claim 1 requires a therapeutically effective amount, claim 4 covers 70-130 mg per administration, and claims 3, 5, 7, 9, and 10 specify 80 mg and 120 mg (including oral once daily for claims 3, 9, and 10).
3) Can design-around be done by changing from oral to another route?
Claim 2 includes multiple non-oral forms, and claim 1 is not route-limited. A route-only change is unlikely to eliminate risk; dose and patient predicate remain key.
4) Does a sustained-release formulation avoid the patent?
Claim 2 explicitly includes galenic forms or devices assuring prolonged and/or slow release, so sustained-release alone is not a clean workaround.
5) What is the most infringement-sensitive element in the claim text?
The combined clinical predicate and regimen: PBC with inadequate UDCA response plus elafibranor administration, particularly oral once daily 80 or 120 mg.
References
[1] United States Patent No. 11,185,519 (claims provided in user prompt).
